Outcomes of treatment of latent tuberculosis infection in children with two different regimens Source: Eur Respir J 2006; 28: Suppl. 50, 487s Year: 2006
Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2015; 46: 1397-1406 Year: 2015
Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2016; 47:1594-1595 Year: 2016
Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2016; 47:1592-1594 Year: 2016
Treatment of latent tuberculosis with 12 weeks isoniazid/rifapentine in clinical practice Source: Eur Respir J, 53 (2) 1801128; 10.1183/13993003.01128-2018 Year: 2019
Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs Source: Eur Respir J, 55 (3) 1902048; 10.1183/13993003.02048-2019 Year: 2020
Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly Source: Eur Respir J, 53 (3) 1802396; 10.1183/13993003.02396-2018 Year: 2019
Multidrug-resistant tuberculosis: treatment outcome after 18 months of invidualised therapy Source: Eur Respir J 2001; 18: Suppl. 33, 314s Year: 2001
Effectiveness of intravenous isoniazid and ethambutol administration in patients with new smear positive drug-susceptible pulmonary tuberculosis with tuberculous meningoencephalitis and HIV co-infection in the intensive phase of treatment Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019
Comparison of compliance of two therapeutic regimens in treatment of latent tuberculosis infection in Belgrade children Source: Eur Respir J 2004; 24: Suppl. 48, 648s Year: 2004
Latent tuberculosis infection in a drug treatment centre Source: Eur Respir J 2002; 20: Suppl. 38, 366s Year: 2002
Diagnosis and treatment of latent tuberculosis infection Source: Eur Respir Monogr 2018; 82: 381-398 Year: 2018
Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection. Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018
Isoniazid hepatotoxicity associated with treatment of latent tuberculosis in patients on anti-TNF treatment Source: Annual Congress 2007 - Clinical tuberculosis Year: 2007
Completion of treatment for latent tuberculosis infection Source: Annual Congress 2011 - Clinical tuberculosis Year: 2011
Latent tuberculosis (infection). Evaluation of a short course treatment with isoniazid, rifampin and pyrazinamid Source: Eur Respir J 2002; 20: Suppl. 38, 567s Year: 2002
Prevalence, screening and treatment of latent tuberculosis among oral corticosteroid recipients Source: Eur Respir J 2014; 44: 1373-1375 Year: 2014
A choice of regimen improves completion for patients with latent TB infection Source: Breathe 2008; 4: 366 Year: 2008
High rate of hepatitis due to treatment with pyrazinamide (PYR) and ethambutol (EMB) for latent tuberculosis infection (LTBI) in subjects exposed to MDR-TB Source: Annual Congress 2005 - Management of tuberculosis pulmonary, extrapulmonary peculiarities Year: 2005
3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review Source: Eur Respir J, 52 (1) 1800395; 10.1183/13993003.00395-2018 Year: 2018